《生命科学》 2024, 36(5): 658-668

瘦素-脂联素比值：代谢健康中的可靠指标

余　维¹ , 钟金清² , 张忠英^1,2,* , 葛胜祥^1,*

¹厦门大学公共卫生学院，厦门 361102 ²厦门弘爱医院医学检验中心，厦门 361009

摘　要：

瘦素- 脂联素比值(leptin-adiponectin ratio, LAR) 将瘦素的促炎和胰岛素抵抗作用与脂联素的抗炎和胰岛素增敏特性相结合，是一种可以反映有关胰岛素敏感性、脂肪组织功能障碍和心血管健康的可靠指标。在临床应用中，LAR 表现出在评估胰岛素抵抗、诊断代谢综合征、衡量心血管风险方面的潜力，与多种疾病密切相关。它的应用范围涵盖了从儿童、青年到老年人的多个年龄段及孕妇等特殊生理状态。该文提供了LAR 作为评估代谢健康的新兴生物标志物的强有力证据，同时指出了当前的挑战和限制，旨在为相关疾病的病情评估、疾病进展、疗效观察以及临床预后的判断等提供科学依据。

通讯作者：张忠英 , Email:zhangzy1121@xmu.edu.cn 葛胜祥 , Email:sxge@xmu.edu.cn

Leptin-adiponectin ratio: a reliable indicator in metabolic health

YU Wei¹ , ZHONG Jin-Qing² , ZHANG Zhong-Ying^1,2,* , GE Sheng-Xiang^1,*

¹School of Public Health, Xiamen University, Xiamen 361102, China ²Medical Laboratory Center of Xiamen Humanity Hospital, Xiamen 361009, China

Abstract:

The leptin-adiponectin ratio (LAR) integrates the  contrasting roles of leptin and adiponectin in metabolic
health, combining the pro-inflammatory and insulin-  esistance properties of leptin with the anti-inflammatory and insulin-sensitizing characteristics of adiponectin. This offers a comprehensive and reliable indicator for  assessing insulin sensitivity, adipose tissue dysfunction, and  cardiovascular health. In clinical applications, LAR has demonstrated potential in diagnosing and evaluating a  range of metabolic disorders, including insulin resistance, metabolic syndrome, and cardiovascular diseases, across  diverse age groups from children to the elderly, and in special physiological conditions such as pregnancy. This paper provides robust evidence supporting LAR as an emerging biomarker in metabolic health assessment and discusses its current challenges and limitations, aiming to establish a scientific basis for disease status assessment, progression monitoring, efficacy observation, and clinical prognosis determination.

Communication Author：ZHANG Zhong-Ying , Email:zhangzy1121@xmu.edu.cn GE Sheng-Xiang , Email:sxge@xmu.edu.cn